AltruBio is a clinical-stage biotechnology company focused on discovering and developing novel therapies for the treatment of various diseases, including colorectal cancer. The company leverages its proprietary technology platform to create immunotherapies aimed at harnessing the body's immune system to fight cancer and other diseases.

AltruBio

AltruBio is developing first-in-class immune-modulators targeting diseases of #immunology and #inflammation. Its world-class global team brings a breadth of expertise in immunology and drug development that will help advance their biologic treatments to patients. Learn more at https://www.altrubio.com/altrubio/en

AltruBio Inc.

Following the close of our Series B fundraising, our President and Chief Executive Officer, Dr. Judy Chou and our Senior Director of Business Development, Edwin Powers are engaging with biotech and pharma leaders across the industry at #BIO2024, building the excitement for our Phase 2 trials in UC and the promising future of next-generation therapies in the I&I space.

The novel immune checkpoint enhancer (ICE) ALTB-268 invented at AltruBio Inc.  has the unique mechanism of action to be potentially more effective and durable. With our recently closed fundraising, we are excited to move forward with our phase 2 program in ulcerative colitis. Read more about AltruBio’s progress in the STAT article here: https://bit.ly/4bX4BeC
#immunecheckpointenhancer #ulcerativecolitis #IBD

We are grateful to receive the biggest raise of the week in biotech industry to accelerate our phase 2 program in order to help patients suffering from ulcerative colitis. https://lnkd.in/gBsmNMBG
#ibd #ulcerativecolitis #immunecheckpointenhancer

Thank you to the New York Stock Exchange NYSE for celebrating our Series B on the historic trading floor! What a surprise!

With over three million individuals in the United States living with ulcerative colitis (UC) and Crohn's disease, there is a clear and urgent unmet medical need. We value the widespread recognition of AltruBio’s oversubscribed Series B raise as we are accelerating our efforts to advance our clinical studies in UC. Check out this article in The Wall Street Journal: https://on.wsj.com/4axd6Mn

Thank you Nasdaq for the surprising congratulations at Times Square today!

COM:ALTRUBIO

AltruBio